Skip to main content

Table 3 Intention to Treat Comparison of Groups on Primary and Secondary Outcomes

From: A novel brief treatment for methamphetamine use disorders in South Africa: a randomised feasibility trial

 

Dependent variable

Days used

Penn total

SD work

SD social life

SD family

CGI

HAM-A

HAM-D

Time period (reference: baseline; type III SS p-value)

0.029

< 0.001

0.023

< 0.001

< 0.001

0.002

0.001

< 0.001

 6 week follow-up

− 2.133** (0.830)

− 5.067*** (1.523)

− 1.367* (0.751)

− 2.233*** (0.755)

− 1.933*** (0.697)

− 0.567* (0.312)

− 2.533* (1.412)

− 1.267 (0.952)

  3 month follow-up

− 1.667** (0.830)

− 9.367*** (1.523)

− 2.067*** (0.751)

− 4.133*** (0.755)

− 3.900*** (0.697)

− 1.133*** (0.312)

− 5.633*** (1.412)

− 4.100*** (0.952)

Treatment group (reference: control; type III SS p-value)

0.343

0.347

0.233

0.791

0.474

0.915

0.319

0.899

  Intervention

1.104 (1.155)

− 2.020 (2.131)

1.129 (0.937)

−  0.242 (0.909)

− 0.645 (0.894)

0.041 (0.387)

− 2.302 (2.458)

0.230 (1.575)

Age at baseline (type III SS p-value)

0.337

0.279

0.106

0.072

0.156

0.093

0.497

0.499

 

− 0.070 (0.072)

− 0.145 (0.133)

− 0.089 (0.054)

− 0.094* (0.051)

− 0.076 (0.053)

− 0.038* (0.022)

0.087 (0.167)

0.052 (0.105)

CGI-severity at baseline (type III SS p-value)

0.197

0.185

0.826

0.449

0.466

N/A

0.006

0.002

 

0.660 (0.505)

− 1.391 (1.037)

− 0.094 (0.424)

0.305 (0.400)

0.303 (0.413)

 

3.489*** (1.225)

2.435*** (0.760)

Number of days in past 2 weeks using meth at baseline (type III SS p-value)

N/A

0.651

0.191

0.774

0.992

0.013

0.381

0.496

  

0.107 (0.236)

0.128 (0.097)

− 0.026 (0.091)

− 0.001 (0.094)

0.091** (0.036)

0.602** (0.265)

0.129 (0.167)

Time period by treatment group interaction (reference: baseline control; type III SS p-value)

0.013

0.169

0.786

0.386

0.672

0.283

0.312

0.529

 6 week follow-up Intervention

− 2.767** (1.173)

0.667 (2.154)

− 0.433 (1.063)

− 0.567 (1.068)

− 0.300 (0.985)

− 0.667 (0.442)

− 2.300 (1.997)

− 1.433 (1.346)

 3 month follow-up Intervention

− 3.267*** (1.173)

3.833* (2.154)

− 0.733 (1.063)

0.900 (1.068)

0.567 (0.985)

− 0.533 (0.442)

− 2.900 (1.997)

− 0.267 (1.346)

Constant

7.336** (3.618)

33.193*** (6.648)

8.201*** (2.730)

9.324*** (2.580)

9.194*** (2.655)

5.526*** (0.812)

12.418** (5.975)

9.780** (3.774)

Observations

180

180

180

180

180

180

180

180

Log Likelihood

− 499.304

− 603.844

− 472.698

− 470.088

− 462.489

− 321.576

− 609.198

− 537.667

Akaike Inf. Crit.

1,018.608

1,229.687

967.396

962.175

946.978

663.153

1,238.396

1,095.333

Bayesian Inf. Crit.

1050.083

1264.245

1001.955

996.734

981.537

694.628

1269.870

1126.808

  1. Linear mixed-effects model; p-values entered in italic text; all other values are coefficients (standard error) unless otherwise stated
  2. *p < 0.1; **p < 0.05; ***p < 0.01